FDA endorsed drug ‘Teicoplanin’ discovered more powerful in treating COVID – 19 infection: IIT Delhi research

Overview

• Post By : Kumar Jeetendra


• Source: PTI


• Date: 28 Sep,2020

Clinically approved drug”Teicoplanin” is a potential therapeutic alternative against COVID-19 and may be ten times more effective than many drugs being currently used, a study by Indian Institute of Technology (IIT), Delhi has found.
The research from the institute’s Kusuma School of Biological Science screened an assemblage of 23 approved drugs, which have shown leads towards being curative options for coronavirus.

“While the impact of Teicoplanin was contrasted with other important drugs in use, Teicoplanin was found to be 10-20 fold more effective than the chief drugs used against SARS-CoV-2, such as Lopinavir and Hydroxychloroquine in our laboratory conditions,” said Ashok Patel, Professor at IIT Delhi.

Patel, who led the study was also assisted by Dr Pradeep Sharma from AIIMS. The research has also been published in the International Journal of Biological Macromolecules.

Teicoplanin is an FDA-approved glycopeptide antibiotic, which is regularly used for treating Gram-positive bacterial infections with low toxicity profile in people.

“Recently, there has been a clinical research carried out with Teicoplanin at Sapienza University in Rome. But a more detailed clinical investigation is needed on a large cohort, in various phases mild, moderate and seriously ill patients to complete the definite role of Teicoplanin against COVID-19,” Patel said.

Globally, over 3.2 crore people have been infected with COVID-19, and the complete number of deaths from the deadly virus now stands at over 9.80 lakh.

India’s coronavirus tally galloped past 60 lakh on Monday with 82,170 new situations, while the amount of recoveries jumped to 50.17 lakh after 74,893 more individuals recuperated, the Health Ministry said.

The death toll from the pathogen climbed to 95,542 with 1,039 more deaths. There are 9,62,640 active cases of the coronavirus disease (COVID-19), comprising 15.85 per cent of the caseload, according to the ministry data.

Clinically approved drug”Teicoplanin” is a potential therapeutic alternative against COVID-19 and may be ten times more effective than many drugs being currently used, a study by Indian Institute of Technology (IIT), Delhi has found.
The research from the institute’s Kusuma School of Biological Science screened an assemblage of 23 approved drugs, which have shown leads towards being curative options for coronavirus.

“While the impact of Teicoplanin was contrasted with other important drugs in use, Teicoplanin was found to be 10-20 fold more effective than the chief drugs used against SARS-CoV-2, such as Lopinavir and Hydroxychloroquine in our laboratory conditions,” said Ashok Patel, Professor at IIT Delhi.

Patel, who led the study was also assisted by Dr Pradeep Sharma from AIIMS. The research has also been published in the International Journal of Biological Macromolecules.

Teicoplanin is an FDA-approved glycopeptide antibiotic, which is regularly used for treating Gram-positive bacterial infections with low toxicity profile in people.

“Recently, there has been a clinical research carried out with Teicoplanin at Sapienza University in Rome. But a more detailed clinical investigation is needed on a large cohort, in various phases mild, moderate and seriously ill patients to complete the definite role of Teicoplanin against COVID-19,” Patel said.

Globally, over 3.2 crore people have been infected with COVID-19, and the complete number of deaths from the deadly virus now stands at over 9.80 lakh.

India’s coronavirus tally galloped past 60 lakh on Monday with 82,170 new situations, while the amount of recoveries jumped to 50.17 lakh after 74,893 more individuals recuperated, the Health Ministry said.

The death toll from the pathogen climbed to 95,542 with 1,039 more deaths. There are 9,62,640 active cases of the coronavirus disease (COVID-19), comprising 15.85 per cent of the caseload, according to the ministry data.